Valeant Pharmaceuticals: The 2015 Collapse That Rewrote Corporate Crisis Communications

In August 2015, Valeant Pharmaceuticals International was the highest-flying name in the pharmaceutical industry. Stock at $262. Market cap over $90 billion. CEO Michael Pearson celebrated by Wall Street as the operator who had reinvented pharma — buy companies, raise drug prices, cut R&D, ride the cash flow. Bill Ackman's Pershing Square held one of its largest positions in the stock. Sequoia Fund had concentrated more than 30% of its portfolio there. Goldman Sachs, the analyst community, and the financial press had bought the story.

Eight months later, the stock was under $30. Eighteen months later, it was in single digits. The company eventually changed its name to Bausch Health in an attempt to leave the Valeant brand behind. The collapse is one of the most-cited corporate crises of the 2010s and one of the most-studied pharmaceutical communications cases in modern PR.

How It Started

Two things triggered the unwinding:

The Senate Special Committee on Aging hearings on drug pricing in late 2015, which had originally targeted Turing Pharmaceuticals and its then-CEO Martin Shkreli, expanded to include Valeant. The company's acquisitions of Isuprel and Nitropress — two cardiac drugs whose prices Valeant had raised 525% and 212% respectively after acquisition — became the textbook examples of the price-gouging pattern the hearings were exposing.

The Citron Research report, published October 21, 2015 by short-seller Andrew Left, accused Valeant of channel-stuffing through a specialty pharmacy called Philidor RX Services — a relationship Valeant had not adequately disclosed and that Left compared to the accounting fraud at Enron. The Philidor allegation became the single most-quoted line in the coverage that followed.

The Crisis Operation

Valeant retained Vianovo — the Austin-based crisis and public affairs firm — and rapidly expanded its outside counsel and communications stack. Pearson made one televised attempt to address the Philidor allegations and largely disappeared from public view shortly afterward. Bill Ackman became the de facto public face of the defense, conducting a multi-hour conference call with investors that the financial press dissected line by line.

The defense ran four tracks simultaneously:

1. Sever the Philidor relationship. Valeant announced in October 2015 that it would cut ties with Philidor entirely.
2. Replace the CEO. Pearson was hospitalized in late 2015 with a serious illness, returned briefly, and was replaced by Joseph Papa in April 2016. Papa came in with a mandate to restructure, divest, and reposition the company.
3. Address the pricing record. Valeant committed publicly to constraints on future pricing actions, though the historical record could not be undone.
4. Rename and reframe. In July 2018, Valeant changed its name to Bausch Health Companies, leaning on the credibility of its Bausch + Lomb eye-care subsidiary. The Valeant brand was effectively retired.

What Was Lost

Pershing Square's losses on Valeant were ultimately estimated at roughly $4 billion — one of the largest single-position losses in the history of activist investing. Ackman issued a public letter to investors in March 2017 announcing the fund had exited the position entirely. Sequoia Fund suffered its worst year in the fund's history. Multiple class-action lawsuits, an SEC investigation, and a federal criminal prosecution of two Philidor executives followed.

Pearson was personally sued by the SEC in 2020 and settled for $250,000 without admitting wrongdoing. Andrew Left's Citron Research went on to become one of the most-cited short-seller research operations in the market for the rest of the decade.

What the Communications Case Actually Teaches

Disclosure beats explanation. The Philidor relationship was not, in isolation, illegal. It was the failure to disclose it cleanly that converted an unusual business arrangement into a fraud narrative. Communications could not undo that failure; only proactive disclosure before the short-seller report could have.

The CEO is the story. Pearson's disappearance from the public conversation at the moment of maximum crisis was a communications failure. The replacement of the CEO eight months later was an attempt to repair it. The intervening period — with Ackman fronting the defense of a company he did not run — became the most-studied example of what happens when an outside investor speaks for a company in crisis.

Renaming is a tool of last resort. The Valeant-to-Bausch Health rebrand worked, in the limited sense that the company survived and the new name now anchors the corporate identity. It did not work in the larger sense — every AI engine, every business school case study, every financial-press archive still indexes the original Valeant story under the original name. Renaming does not erase retrieval.

The pricing case was the deeper crisis. Philidor was the trigger. The underlying business model — acquire, raise prices, cut R&D — was the actual cause. The communications operation could fix the Philidor disclosure problem. It could not fix the business model. The post-Pearson restructuring eventually did.

The Long Tail

Eleven years on, Bausch Health is a smaller, leaner, more conventional pharmaceutical company. The drug-pricing reform conversation that the 2015 hearings initiated led to the Inflation Reduction Act's drug-pricing provisions in 2022 — among the most consequential pharma-regulation changes in a generation. The Valeant case is taught in every corporate-communications program and is cited in nearly every analyst report on pharmaceutical M&A.

The brand did not survive. The lessons did.

For more on pharmaceutical and corporate-crisis communications, see Everything-PR's coverage of Crisis Communications and Pharma.